Does Cigna Cover Weight Loss Treatment in Hawaii? A 2026 Guide

Last updated: July 17, 2026

Cigna Hawaii Weight Loss Coverage — Key Facts (2026):

• PBM: Express Scripts (ESI) — Cigna’s pharmacy benefit manager in Hawaii
• Zepbound on ESI Formulary: ESI did NOT remove Zepbound — it remains Tier 3–4 with prior authorization. This is a significant differentiator from CVS/Caremark, which removed Zepbound in mid-2025 and only reinstated it October 1, 2026.
• Wegovy (semaglutide): Typically Tier 3–4 on ESI with prior authorization required (BMI criteria)
• HI EPCS: Entirely inapplicable to weight loss medications — none fall under Hawaii’s Schedule II EPCS mandate (HRS § 329-38.5)
• Medicare GLP-1 Bridge: Does NOT apply to Cigna commercial plans — this $50/month program is for Medicare Advantage members only
• Hawaii Parity Law (§ 431M-1): Governs mental health and substance use disorder only — does NOT extend to weight loss medications

If you have Cigna insurance in Hawaii and are exploring weight loss treatment options, understanding what your plan may cover can help you make informed decisions before booking a provider visit. This guide explains how Cigna’s pharmacy benefit manager Express Scripts handles GLP-1 medications, oral weight loss drugs, and what prior authorization requirements may apply to Hawaii members in 2026.

See if you may qualify for weight loss treatment through Klarity Health →

How Cigna Covers Weight Loss Medications in Hawaii

Cigna commercial plan members in Hawaii access prescription benefits through Express Scripts (ESI). Unlike CVS/Caremark — which temporarily removed Zepbound from its commercial formularies in mid-2025 and reinstated it on October 1, 2026 — ESI maintained Zepbound on its commercial formulary throughout this period at Tier 3–4 with prior authorization. This makes ESI-managed Cigna plans an important option for patients seeking GLP-1 coverage.

Coverage for specific weight loss medications varies depending on your plan design, employer benefit structure, and whether your employer has chosen to include obesity pharmacotherapy in the benefit. Many employer-sponsored Cigna plans in Hawaii do include GLP-1 medication coverage, though prior authorization is typically required for branded agents.

ESI Weight Loss Drug Formulary (2026 — Cigna Hawaii)

Tier placements and prior authorization requirements may vary by specific plan design. Always verify your plan’s formulary at mycigna.com or by calling 1-800-244-6224.

The Zepbound Differentiator: ESI vs. CVS/Caremark

One of the most significant formulary developments in 2025–2026 for patients seeking GLP-1 coverage is the Zepbound (tirzepatide) situation. CVS/Caremark removed Zepbound from its commercial formularies in mid-2025, causing significant disruption for Aetna and HMSA members in Hawaii. CVS/Caremark reinstated Zepbound on October 1, 2026.

Express Scripts (ESI) — Cigna’s PBM — did not remove Zepbound during this period. Hawaii Cigna commercial members who may have been considering switching plans solely for GLP-1 access should note that ESI’s formulary continuity represents a meaningful benefit compared to CVS/Caremark-managed plans during the disruption window.

Regardless of formulary tier, prior authorization is typically required for Zepbound under Cigna/ESI. Standard criteria often include documentation of BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea), along with evidence of prior lifestyle modification attempts.

Prior Authorization for Weight Loss Medications

Most branded weight loss medications on the ESI formulary require prior authorization before Cigna will cover them. The PA process for weight loss medications typically involves:

• BMI documentation: BMI ≥30 (obesity) or BMI ≥27 with qualifying weight-related comorbidity
• Prior lifestyle intervention: Evidence of participation in a supervised diet, exercise, or behavioral modification program (typically 3–6 months)
• Clinical notes: Provider documentation of medical necessity, including relevant comorbidities
• Step therapy: For some plans, an oral agent (Contrave, phentermine) may be required before a GLP-1 is covered

PA requests for Cigna Hawaii members are submitted by your prescribing provider through Availity (availity.com) or the Cigna provider portal at cigna.com/providers. Most PA decisions are returned within 2–3 business days; urgent requests may receive a response within 72 hours.

If your PA is denied, you have the right to appeal through Cigna’s internal appeals process. You may also request a peer-to-peer review between your provider and Cigna’s medical director. If internal appeals are exhausted, you can escalate to Hawaii’s external review process through the Hawaii Insurance Division at 1-808-586-2790.

Electronic Prescribing (EPCS) for Weight Loss Medications in Hawaii

Hawaii’s Electronic Prescribing for Controlled Substances law (HRS § 329-38.5) applies to Schedule II controlled substances only. Weight loss medications fall outside this mandate:

• GLP-1 medications (Zepbound, Wegovy, Saxenda, Ozempic): Non-scheduled — EPCS requirement entirely inapplicable
• Contrave (naltrexone/bupropion): Non-scheduled — EPCS inapplicable
• Orlistat / Xenical: Non-scheduled — EPCS inapplicable
• Phentermine: Schedule IV controlled substance — NOT subject to HRS § 329-38.5 (Schedule II only; Schedule IV is exempt from Hawaii’s EPCS mandate)
• Qsymia (phentermine/topiramate): Schedule IV — NOT subject to HRS § 329-38.5

This contrasts with states such as West Virginia, where W. Va. Code § 60A-4-403a extends the EPCS mandate to all controlled substances — including Schedule IV phentermine and Qsymia. In Hawaii, providers may issue paper or electronic prescriptions for phentermine and Qsymia without EPCS compliance concerns.

Hawaii Mental Health Parity Law and Weight Loss Coverage

Hawaii’s Mental Health Parity Law (Haw. Rev. Stat. § 431M-1 et seq.) requires insurers to provide mental health and substance use disorder benefits at parity with medical/surgical benefits. This law governs mental health and substance use disorders only — it does not extend to weight loss treatment, obesity medication coverage, or GLP-1 pharmacotherapy.

Weight loss medication coverage for Cigna Hawaii commercial members is governed instead by:

• ACA Essential Health Benefits (EHB): Establishes baseline benefit categories, though obesity pharmacotherapy is not explicitly mandated as an EHB in all states
• ERISA: Most Hawaii employer-sponsored Cigna plans are self-funded ERISA plans, giving employers significant flexibility in determining whether to include weight loss drug coverage
• Your specific plan document (Summary Plan Description): The definitive source for what your Cigna plan covers

If your Cigna plan does not currently include GLP-1 coverage, this is typically an employer benefits design decision rather than a regulatory mandate. Employees may advocate for benefit changes at open enrollment or through HR.

Hawaii Prepaid Health Care Act (HRS § 393)

Hawaii’s Prepaid Health Care Act (HRS § 393-7) requires most employers to provide health insurance to employees working 20 or more hours per week — one of the only such mandates in the United States. This law applies to Cigna commercial plans sold to Hawaii employers.

The Hawaii Prepaid Health Care Act sets a floor for health benefit requirements but does not specifically mandate obesity pharmacotherapy or GLP-1 medication coverage. Coverage for weight loss medications under your Cigna Hawaii plan will depend on your specific plan design and employer election.

For questions about benefit requirements under the Hawaii Prepaid Health Care Act, contact the Hawaii Department of Labor and Industrial Relations (DLIR) at 1-808-586-8777.

Medicare GLP-1 Bridge: Important Clarification for Cigna Hawaii Members

Effective July 1, 2026, CMS launched a Medicare GLP-1 Bridge program providing eligible Medicare Advantage and Part D members access to Wegovy, Zepbound, and Foundayo at approximately $50/month via CMS. This program applies to Medicare Advantage members only.

Cigna offers commercial (non-Medicare) health insurance in Hawaii. Cigna commercial plan members are not eligible for the Medicare GLP-1 Bridge program. If you have a Cigna commercial plan through your employer or the individual market, your GLP-1 coverage is determined by your ESI formulary and plan design — not by this Medicare program.

Weight Loss Conditions Commonly Treated

Weight loss treatment through Klarity Health may address:

• Obesity (BMI ≥30) — the primary indication for GLP-1 medications under most Cigna/ESI PA criteria
• Overweight with comorbidities (BMI ≥27 + condition) — including hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea
• Metabolic syndrome — cluster of conditions including high blood pressure, high blood sugar, and abnormal cholesterol
• Weight gain associated with medication use — including weight gain from psychiatric medications
• Lifestyle and behavioral weight management — when pharmacotherapy alone is insufficient

How to Verify Your Cigna Hawaii Weight Loss Coverage

Before booking a weight loss provider visit, take these steps to understand your potential coverage:

1. Log in to myCigna.com and review your plan’s drug formulary under “Coverage & Benefits” → “Prescription Drug Coverage”
2. Check for exclusions: Look for “weight management drugs,” “anti-obesity medications,” or “GLP-1 medications” in your plan’s exclusion list
3. Call Cigna member services at 1-800-244-6224 and ask specifically: “Does my plan cover Zepbound or Wegovy for weight management, and what are the prior authorization criteria?”
4. Ask your HR department whether your employer has added obesity pharmacotherapy as a covered benefit — this is a plan-level election
5. Consult Express Scripts at 1-800-835-3784 for formulary-specific questions about your pharmacy benefit

Weight Loss Treatment Through Klarity Health

Klarity Health connects patients across Hawaii with licensed providers who specialize in weight management. With 2,000+ providers in the network, Klarity Health offers telehealth-based weight loss consultations that may include evaluation for GLP-1 medications and other pharmacotherapy options.

Klarity Health can work with your Cigna insurance information to help you understand your potential coverage, though patients should always verify their specific benefits directly with Cigna before booking.

Check if you may qualify for weight loss treatment through Klarity Health →

Contact Information

• Cigna Member Services (Hawaii): 1-800-244-6224 | myCigna.com
• Express Scripts (ESI) Pharmacy: 1-800-835-3784 | express-scripts.com
• Cigna Provider Portal (PA submissions): cigna.com/providers
• Availity (PA portal): availity.com
• Hawaii Insurance Division: 1-808-586-2790 | insurance.hawaii.gov
• Hawaii DLIR (Prepaid Health Care Act): 1-808-586-8777 | labor.hawaii.gov
• CMS Medicare Information: 1-800-633-4227 | medicare.gov

Frequently Asked Questions

Does Cigna cover Zepbound in Hawaii in 2026?

Cigna’s pharmacy benefit manager Express Scripts (ESI) maintained Zepbound on its commercial formulary at Tier 3–4 throughout 2025–2026 — it was not removed, unlike CVS/Caremark (which removed Zepbound and reinstated it October 1, 2026). Prior authorization is typically required. Whether your specific Cigna plan covers Zepbound depends on your plan design and whether your employer has elected to include obesity pharmacotherapy. Verify at myCigna.com or by calling 1-800-244-6224.

Does the Medicare GLP-1 Bridge ($50/month) apply to my Cigna commercial plan?

No. The CMS Medicare GLP-1 Bridge program launched July 1, 2026 applies exclusively to Medicare Advantage and Part D members. Cigna commercial plan members are not eligible for this program. Your GLP-1 coverage is governed by your ESI formulary and your employer’s plan design.

Does Hawaii’s mental health parity law require Cigna to cover weight loss medications?

No. Hawaii’s Mental Health Parity Law (Haw. Rev. Stat. § 431M-1 et seq.) applies to mental health and substance use disorder benefits only. It does not require coverage of weight loss medications or GLP-1 pharmacotherapy. Weight management drug coverage is an employer benefits design decision under ERISA and ACA EHB frameworks.

Does Hawaii’s EPCS law apply to phentermine prescriptions from my Cigna-covered provider?

No. Hawaii’s Electronic Prescribing for Controlled Substances law (HRS § 329-38.5) applies to Schedule II controlled substances only. Phentermine and Qsymia are Schedule IV controlled substances, which are not subject to Hawaii’s EPCS mandate. Providers may prescribe these medications electronically or on paper without violating HI EPCS requirements.

My Cigna PA for Zepbound was denied — what can I do?

You have the right to appeal. First, request a peer-to-peer review between your provider and Cigna’s medical director — this often resolves denials when the provider can provide additional clinical context. If the internal appeal is denied, you may request external review through the Hawaii Insurance Division at 1-808-586-2790 (insurance.hawaii.gov). The external reviewer is independent of Cigna and their decision is typically binding.

Does the Hawaii Prepaid Health Care Act require employers to cover weight loss drugs?

No. The Hawaii Prepaid Health Care Act (HRS § 393) requires employers to provide health insurance to employees working 20+ hours per week, but it does not specifically mandate obesity pharmacotherapy or GLP-1 medication coverage. Whether weight loss drugs are covered under your Cigna Hawaii plan depends on your employer’s specific benefit elections and plan design.

Disclaimer

This page provides general information about how Cigna insurance and Express Scripts (ESI) may handle weight loss medication coverage in Hawaii and is intended for educational purposes only. Coverage details vary by plan, employer, and individual circumstances. Nothing on this page constitutes a guarantee of coverage or benefits. Always verify your specific benefits directly with Cigna (1-800-244-6224) and review your Summary Plan Description before seeking treatment. Klarity Health is not affiliated with Cigna or Express Scripts. Information is current as of July 2026 and subject to change.